Single Inhaler Triple Therapy Effective for COPD Single Inhaler Triple Therapy Effective for COPD
A single inhaler triple therapy provides clinical benefits superior to those of the muscarinic antagonist tiotropium alone in patients with symptomatic chronic obstructive pulmonary disease (COPD), according to the TRINITY trial.Reuters Health Information
ConclusionsOut of e-prescriptions for inhaled medications issued in 2018 in Poland, 15.3% were not redeemed. The degree of primary non-adherence was influenced by age, but not gender. Significant differences between MDIs and DPIs and between inhalers with/without a dosage counter were observed.
AbstractThe coronavirus disease (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and presents with respiratory symptoms which can be life threatening in severe cases. At the start of the pandemic, allergy, asthma, and chronic obstructive pulmonary disease (COPD) were considered as risk factors for COVID-19 as they tend to exacerbate during respiratory viral infections. Recent literature has not shown that airway allergic diseases is a high-risk factor or that it increases the severity of COVID-19. This is due to a decrease in Angiotensin-converting enzyme 2 (ACE2) gene expression in the ...
This article presents the data about the clinical features of ACO, the current information regarding the underlying pathophysiology of the syndrome, and current understanding of therapeutic options.
This study analyzed cross-sectional datasets of adults (aged ≥ 40 years) in the Korean National Health and Nutrition Examination Survey 2010-2016. Health-related QoL was assessed using the 3-level EuroQoL 5-dimension component (EQ-5D-3L) index score. The presence of chronic cough and other conditions were defined using structured questionnaires. RESULTS: The prevalence of chronic cough was 3.48% ± 0.17% among adults aged ≥ 40 years. The overall EQ-5D-3L index score was significantly lower in subjects with than without chronic cough (0.79 ± 0.01 vs. 0.86 ± 0.00, P
Wondering when to get your flu shot? The best time is before influenza (flu) starts circulating widely. For most people, September or October is ideal for protection through the whole flu season, as the immune response from the vaccine wanes over time. And while changes and restrictions due to COVID-19 may make getting a flu vaccine less convenient for some this year, the pandemic makes it more important than ever. Why do I need to get a flu vaccine yearly? Influenza A and Influenza B cause most cases of flu in humans. Both have many strains that constantly change, accumulating genetic mutations that disguise them from the...
The pandemic due to the infection by the betacoronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which began in Wuhan, People ’s Republic of China, in December 2019, causing the infectious coronavirus disease 2019 (COVID-19),1 surpassed 21 million infections and more than 700,000 deaths globally,2 with numbers that continue to rise. The prognosis of SARS-CoV-2 infection worsens when comorbidities such as high blood press ure (HBP), chronic obstructive pulmonary disease, diabetes mellitus (DM), cardiovascular disease, and obesity are associated.
Mild cognitive impairment (MCI) is a transitional state between the cognition of normal aging and mild dementia. People with MCI have an increased risk of developing Alzheimer ’s disease at a rate of 10% to 15% per year or prodrome of dementia.1 Cognitive impairment is a complex chronic condition, and its prevalence increases with age.2 The presence of coexisting chronic conditions such as chronic obstructive pulmonary disease and vision or hearing impairment increases healthcare utilization and contributes to a higher risk of serious health outcomes.
(Rutgers University) A Rutgers-led team discover a protein produced by nervous system may be key to treating inflammatory diseases like asthma, allergies, chronic fibrosis and chronic obstructive pulmonary disease (COPD)
Findings seen among Medicare beneficiaries, particularly those with asthma, COPD, or both
Respiratory viral illnesses are a well-established trigger of asthma exacerbations in children and adults1 and risk factor for poor outcomes and high health care utilization.2 Early studies from China identified chronic pulmonary disease as a risk factor3 for novel coronavirus disease 2019 (COVID-19) severity4 and death.5 US-based studies report that approximately 7% to 9% of hospitalized patients with COVID-19 had chronic lung disease,6,7 with asthma more prevalent than chronic obstructive pulmonary disease (COPD) (9% vs 5.4%, respectively).